Introduction {#Sec1}
============

Severe combined immunodeficiency due to adenosine deaminase deficiency is a rare autosomal recessive disease (ADA-SCID, OMIM \# 102,700) caused by mutations in the gene encoding the enzyme ADA type 1, resulting in impairment of the purine salvage pathway \[[@CR1]--[@CR3]\]. This defect in purine metabolism primarily affects lymphocyte development and function resulting in varying degrees of immune deficiency \[[@CR4]\].

Several studies demonstrate that ADA-SCID is a systemic disease, and thanks to improved survival, an increasing number of non-immune manifestations are being recognized and reported \[[@CR1]--[@CR5]\].

At present, no study describes abnormalities in the development of genitalia or in the pubertal progression of ADA-SCID patients treated for their underlying immune disorder.

Methods {#Sec2}
=======

In this report, we describe data collected retrospectively on the urogenital system and pubertal development of 86 ADA-SCID patients followed in the period 2000--2017: 51 males and 35 females with an age range from 4 months to 30 years were included in this analysis (Table [1](#Tab1){ref-type="table"}). Patients were from different ethnicities, and there was a high prevalence of consanguinity (51%). Previous treatments included enzyme replacement therapy (PEG-ADA ERT), gene therapy (GT), or allogeneic bone marrow transplantation (BMT) as single therapy or given in various combinations (Table [1](#Tab1){ref-type="table"}).Table 1Sample description, sex, origin, parents' consanguinity, ADA-SCID treatment, and years of follow-upN°sexOriginCADA mutationTreatmentYears of follow-up § (age)1FSouth America/HispanicYesCompound heterozygous, c.320 T \> C, p.L107P/c.632G \> A, p.R211HHaploidentical BMT° ➔ GT^1^➔PEG-ADA15 (3--18 y)2MSouth America/HispanicNoCompound heterozygous, c.221G \> T, p.G74V/c.845G \> A, p.R282QHaploidentical BMT° ➔ GT^1^14 (1--15 y)3FArabic/WhiteYesHomozygous c.845G \> A, p.R282QHaploidentical BMT° ➔ PEG-ADA ➔ GT^1^13 (1--14 y)4FArabic/WhiteYesCompound heterozygous, c.646G \> A, p.G216R/c.956_960delAAGAG; p.E319GfsX3PEG-ADA ➔ GT^1^11 (1--12 y)5MEurope/WhiteYesHomozygous c.632G \> A, p.R211HPEG-ADA ➔ GT^1^12 (5--17 y)6MEurope/WhiteNoCompound heterozygous, c.646G \> A, p.G216R/c.872C \> T, p.S291LPEG-ADA ➔ GT^1^11 (0--11 y)7MEurope/WhiteNoHomozygous c.478 + 2 T \> **C**PEG-ADA ➔ GT^1^10 (1--11 y)8FArabic/WhiteYesHomozygous c.646G \> A, p.G216RHaploidentical BMT° ➔ PEG-ADA ➔ GT^1^8 (0--8 y)9MSouth America/HispanicYesHomozygous c.632G \> A, p.R211HPEG-ADA ➔ GT^1^9 (0--9 y)10MNorth America/WhiteNoCompound heterozygous, c.646G \> A, p.G216R/c.956_960delAAGAG; p.E319GfsX3PEG-ADA ➔ GT^1^9 (1--10 y)11MSouth AsiaYesHomozygous c.606 + 5G \>? (Exon6, splice donor site + 5--- no more data available)PEG-ADA ➔ GT^1^9 (0--9 y)12MNorth America/WhiteNoCompound heterozygous, c.646G \> A, p.G216R/Exon10, deletion + 6 c.975 + 6TdelPEG-ADA ➔ GT^1^8 (6--14 y)13FAfrica/WhiteNoHomozygous: c.466C \> T, p.R156CPEG-ADA ➔ GT^1^8 (2--10 y)14MAfrica/BlackNoHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ GT^1^6 (2--8 y)15MAfrica/BlackYesHomozygous, c.881C \> A, p.T294KPEG-ADA ➔ GT^1^ ➔ MSD BMT^2^4 (1--5 y)16MArabic/WhiteYesHomozygous, c.956_960delAAGAG, p.E319GfsX3PEG-ADA ➔ GT^1^5 (2--7 y)17FEuropean/WhiteNoCompound heterozygous, c.632G \> A, p.R211H/c.646G \> A, p.G216RPEG-ADA ➔ GT^1^2 (0--2 y)18MEurope/HispanicNoCompound heterozygous, c.467G \> A, p.R156H / c.646G \> A, p.G216RPEG-ADA ➔ GT^1^ ➔ MUD BMT\*3 (2--5 y)19MEurope/WhiteYesCompound heterozygous, c.385G \> A, p.V129M /(second mutation not identified)PEG-ADA16 (14--30 y)20FEurope/WhiteUnkHomozygous, c.385G \> A, p.V129MPEG-ADA23 (4--27 y)21FEurope/WhiteNoHomozygous, c.499delG**,** pV167PPEG-ADA12 (6--18 y)22MEurope/WhiteYesHomozygous, c.632G \> A, p.R211HPEG-ADA17 (3--20 y)23MEurope/WhiteYesHomozygous, c.632G \> A, p.R211HPEG-ADA ➔ MSD BMT^3^10 (0--10 y)24MEurope/WhiteUnkHomozygous, c.632G \> A, p.R211HPEG-ADA ➔ MSD BMT°6 (5--10 y)25MSouth America/HispanicNoHomozygous, c.845G \> A, p.R282QPEG-ADA ➔ MUD BMT°1 (0--1 y)26FEurope/WhiteUnkExon 3, insertion (no more data available)PEG-ADA ➔ MSD BMT°14 (0--14 y)27MEurope/WhiteNoCompound heterozygous, c.466C \> T, p.R156C/c.955_959GAAGA, p.E320GfsX3PEG-ADA ➔ MUD BMT°13 (1--14 y)28MEurope/WhiteUnkNDHaploidentical BMT\*15 (0--15 y)29FEurope/WhiteUnkNDPEG-ADA ➔ MUD BMT\*11 (0--11 y)30FSouth AsiaUnkHomozygous, c.424C \> T, p.R142XPEG-ADA ➔ MSD BMT°13 (0--13 y)31MUnkUnkHomozygous, c.424C \> T, p.R142XPEG-ADA ➔ MSD BMT°17 (0--17 y)32FAfrica/BlackYesHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ MSD BMT°18 (0--18 y)33MEurope/White IrishUnkHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MFD BMT°17 (0--17 y)34FSouth AsiaYesNDPEG-ADA ➔ MFD BMT°18 (0--18 y)35FEurope/WhiteUnkCompound heterozygous, c.363-1G \> C/c.364G \> A, p.G122RPEG-ADA ➔ MUD BMT^4^18 (0--18 y)36MEurope/WhiteYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MFD BMT°17 (0--17 y)37FEurope/WhiteYesNDPEG-ADA ➔ MSD BMT°16 (0--16 y)38FEurope/White IrishYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MFD BMT°15 (0--15 y)39MAfrica/BlackYesHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ GT^5^17 (0--17 y)40MAfrica/BlackNoHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ MFD BMT°14 (0--14 y)41MAfrica/BlackYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MSD BMT°13 (0--13 y)42FAfrica/BlackNoHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ MUD BMT^6^14 (0--14 y)43MSouth Asian heritageYesHomozygous, c.716G \> A, p.G239DPEG-ADA ➔ MSD BMT°12 (0--12 y)44MEurope/WhiteNoCompound heterozygous, c.367delG, p.D123TfsX10/c.956_960delAAGAG; p.E319GfsX3PEG-ADA ➔ GT^5^13 (0--13 y)45FEurope/WhiteNoCompound heterozygous, c.467G \> A, p.R156H/c.478 + 1G \> APEG-ADA ➔ GT (first)^5^ ➔ GT (second)^7^13 (2--15 y)46MSouth AsiaYesHomozygous, c.716G \> A, p.G239DPEG-ADA ➔ MSD BMT°11 (0--11 y)47FEurope/WhiteYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MFD BMT°11 (1--12 y)48MArabic /whiteYesHomozygous, c.956_960delAAGAG; p.E319GfsX3PEG-ADA ➔ GT^5^8 (0--8 y)49MArabic/WhiteYesHomozygous, c.385G \> A, p.V129MPEG-ADA ➔ MSD BMT°5 (1--6 y)50MEurope/WhiteNoNDPEG-ADA ➔ GT^5^3 (1--4 y)51FAfrica/BlackYesHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ MSD Cord°10 (0--10 y)52MAfrica/BlackYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ GT^5^11 (0--11 y)53FSouth AsiaYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MMUD Cord^8^9 (0--9 y)54FSouth AsiaYesHomozygous, c.703C \> T, p.R235WPEG-ADA ➔ MMUD Cord^8^10 (0--10 y)55MArabic/WhiteYesHomozygous, c.428dupA, p.D143EfsX28PEG-ADA ➔ MUD Cord^8^3 (0--3 y)56MEurope/WhiteNoCompound heterozygous, c.466C \> T, p.R156C/c.646G \> A, p.G216RPEG-ADA ➔ GT^5^ ➔ HSCT^7^12 (1--13 y)57MSouth AsiaYesHomozygous, c.646G \> A, G216RPEG-ADA ➔ MUD Cord ➔ MUD PBSC^9^9 (0--9 y)58FSouth AsiaYesHomozygous, c.716G \> A, p.G239DPEG-ADA ➔ MFD BMT°7 (0--7 y)59MEurope/WhiteNoCompound heterozygous, c.955-958delGAAG, p.E320RfsX6/c.1078 + 2 T \> APEG-ADA ➔ GT (first) ➔ GT (second)8 (4--12 y)60FArabic/WhiteYesHomozygous, 1079-15 T \> APEG-ADA ➔ MUD PBSC^5^3 (1--4 y)61MArabic/WhiteYesHomozygous, c.385G \> A, p.V129MPEG-ADA ➔ MFD BMT^10^4 (0--4 y)62MEurope/White IrishYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MFD BMT^0^7 (0--7 y)63MAfrica/BlackYesHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ GT^7^3 (4--7 y)64MSouth AsiaYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ GT^7^7 (0--7 y)65FEurope/WhiteNoCompound heterozygous, c.646G \> A, p.G216R/c.955_959GAAGA, p.E320GfsX3PEG-ADA ➔ GT^7^5 (0--5 y)66FSouth AsiaYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ GT^7^5 (0--5 y)67MArabic/whiteNoCompound heterozygous, c.976-1G \> C/c.302G \> T, p.R101LPEG-ADA ➔ GT (first) ^7^ ➔ GT (second) ^7^9 (1--10 y)68MAfrica/BlackNoHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ GT^7^4 (0--4 y)69FEurope/WhiteNoCompound heterozygous, c.872C \> T, p.S291L/c.986C \> T, p.A329VPEG-ADA ➔ GT^7^4 (1--5  =y)70MAfrica/BlackNoHomozygous: c.7C \> T, p.Q3XPEG-ADA ➔ GT^7^4 (0--4 y)71MAfrica/BlackNoCompound heterozygous, c.603C \> G, p.Y201X/c.632G \> A, p.R211HPEG-ADA ➔ GT^7^4 (0--4 y)72FAfrica/BlackNoHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ GT^7^4 (9--13 y)73FEurope/White IrishYesHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ GT^7^2 (0--2 y)74MEurope/WhiteNoHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ MFD BMT ➔ MSD BMT°2 (0--2 y)75MUnkNoCompound heterozygous, c.320 T \> C, p.L107P/c.632G \> A, p.R211HPEG-ADA ➔ GT^7^1 (1--2 y)76FAfrica/BlackYesHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ GT^7^3 (0--3 y)77MEurope/White IrishNoHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ GT^7^2 (0--2 y)78MEurope/WhiteYesCompound heterozygous, c.310C \> A, p.P104T/c.646G \> A, p.G216RPEG-ADA ➔ GT^7^2 (0--2 y)79FEurope/WhiteYesCompound heterozygous, c.43C \> G, p.H15D/c.757_758dupCGPEG-ADA ➔ GT^7^2 (0--2 y)80FEurope/WhiteNoHomozygous, c.646G \> A, p.G216RPEG-ADA ➔ GT^7^2 (0--2 y)81MAfrica/WhiteNoHomozygous, c.704G \> A, p.R235QPEG-ADA ➔ GT^7^1 (2--3 y)82MEurope/White IrishYesHomozygous, c.646G \> A, G216RPEG-ADA ➔ GT^7^2 (0--2 y)83FEurope/WhiteNoHomozygous, c.320 T \> C, p.L107PPEG-ADA ➔ GT^7^084MAfrica/BlackYesHomozygous, c.7C \> T, p.Q3XPEG-ADA ➔ GT^7^1 (0--1 y)85FEurope/White IrishYesHomozygous, c.646G \> A, G216RPEG-ADA ➔ GT^7^086FEurope/White-Africa/BlackNoCompound heterozygous, c.482G \> A, p.W161X/c.1078 + 2 T \> APEG-ADA ➔ GT^7^0*C* parents' consanguinity, *Unk* unknown, *§* years of follow-up are considered time from the first diagnostic test available to the last. In parentheses, age of the diagnostic test available--age of the last diagnostic test available. *ND* not done, *BMT* bone marrow transplantation, *GT* gene therapy, *MSD* BMT from matched sibling donor, *MFD* BMT from matched family donor, *MUD* BMT from matched unrelated donor, *MMUD* BMT from mismatched unrelated donor, *PBSC* peripheral blood stem cells, *Cord* cord blood cellsIn the column treatment superscript numbers:\*Unknown^0^No conditioning agents^1^Busulfan (single agent, non myeloablative)^2^Reduced toxicity regimen Treo/Flu^3^Reduced intensity conditioning (RIC) Bu/Flu^4^RIC Flu/Melph/ATG^5^Melphalan (single agent)^6^RIC Flu/Melph/Campath^7^Low-dose busulfan (AUC \~ 20)^8^Myeloablative conditioning (MAC) Treo/Cy^9^MAC Treo/Flu^10^Campath (single agent)

Patients in our cohort received immunological follow-up in five hospitals: 23 patients have been followed at our center, 1 patient at Bambin Gesù Hospital in Rome, 2 patients at Hospital Meyer in Florence, 1 patient at Hospital in Padova, and 59 patients in Great Ormond Street Hospital, London. Italian hospitals are part of the AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) and IPINET (Network Italiano Immunodeficienze Primitive) network.

Patients or their guardians provided written informed consent according to local consent procedures. This report was performed in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration and its later amendments.

We collected the information registered during the immunological follow-up. Medical history, clinical data, routine blood tests, and ultrasound scans performed as part of patients' follow-up were recorded in patients' notes. If patients presented with clinical issues during the follow-up, additional investigations were performed. In male patients, we documented the number of patients with cryptorchidism, whether cryptorchidism was unilateral or bilateral, congenital (testis not present in the scrotum from birth by 3 months of age), or acquired (testis that was originally present in the scrotum at birth but ascends later) \[[@CR6]\] or if the cryptorchidism solved spontaneously or required orchiopexy, the age of surgery, and any recurrences. We registered any urological malformation associated with cryptorchidism and the presence of phimosis and requirement for circumcision. Analyzing the complete cohort of patients, pubertal progression was evaluated at every clinical evaluation available for follow-up in both males and females. We documented the age of spontaneous puberty and every case of precocious or late puberty. Female patients underwent abdominal US scan as part of the follow-up; we documented data of any alteration of gonads at US scan. As markers of puberty, the following blood tests were performed in the majority of patients: luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (male patients), or estradiol (female patients). Analysis of these biomarkers (measured using fluorimetric methods) together with clinical evaluation of puberty allows evaluation of the hypothalamus-pituitary-gonad axis function. Moreover, if these hormones are evaluated in the first 3--6 months of life, it is possible to identify mini-puberty during which LH and FSH increase as it happens during puberty. This is a physiologic hormonal fluctuation without clinical manifestations associated with sex steroids rising to level reached in early-middle pubertal levels, without peripheral effects. If mini-puberty is identified with blood tests, it suggests normal hypothalamus-pituitary-gonad axis function. It has been hypothesized that this hormonal phase has a role in physiologic descent of testis in the first year of life in transient congenital cryptorchidism \[[@CR6]--[@CR9]\].

Results {#Sec3}
=======

Regarding genital development, results differed between males and females.

Of 51 male patients, 11 (22%) presented congenital undescended testes; of those, 6 (54.5%) were bilateral and 7 (63.6%) required orchidopexy, respectively (Table [2](#Tab2){ref-type="table"}). Eight out of 51 (16%) presented acquired undescended testes and among these 3/8 were bilateral and 7/8 required orchidopexy. None of the patients presenting with undescended testes were born at \< 36 weeks gestation. Six of 11 patients with congenital undescended testes had consanguineous parents (54%, Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Among other urogenital abnormalities seen, 3/51 patients presented with inguinal hernia requiring surgical intervention, 6/51 presented micropenis of whom 4 had associated cryptorchidism, and one subject had posterior urethral valves. Nine out of 51 (18%) presented phimosis, and 5/9 were treated with circumcision (Table [2](#Tab2){ref-type="table"}).Table 2Male sample, urogenital abnormalities, pubertal development, hormonal tests, and testis US scanN°WGCUTAUTTreatment of undescended testesOther urogenital diseasesPubertyTestis structure at US scanHypothalamus-pituitary-gonads axis2≥ 37LeftRight (9 y)Left orchidopexy 2 y and 7 monthsRight orchidopexy 9 y and 11 months. No relapsePhimosisPubescent at 15 y (G2P4)Dyshomogeneous (hyporeflectant areas) since 14 yPhysiologic activation536RightNoRight orchidopexy. No relapse1) Phimosis2) inguinal herniaPubescent at 15 y G5NormalPhysiologic activation636 + 1BilatNoBilateral orchidopexy 2 y and 3 months. No relapsePhimosisPrepubescent at 10 yNormalNot activated7≥ 37NoNoNAPhimosisPrepubescent at 11 yNDNot activated9≥ 37NoRight (6 y)Right orchidopexy 7 y and 2 months. No relapsePhimosisPrepubescent at 9 yHyporeflectant areas since 13 yNot activated10≥ 37noNoNANoPrepubescent at 8 yNDNot activated11≥ 37BilatNoGonadoreline not effective. Bilateral orchidopexy 3 y. Bilateral relapseGonadoreline not effective. Left orchidopexy 5y 6mo. Bilateral relapse 7 y1) Phimosis2) Micropenis3) Posterior urethral valve left megaureterNormal mini-pubertyPrepubescent at 9 yNDNot activated1232noNoNANoPrepubescent at 13 yHomogenous but less reflectant since 11 yNot activated14≥ 37LeftBilat (7 y)Congenital undescended testes spontaneously solvedBilateral orchidopexy 8 y. No relapsePhimosisPrepubescent at 8 yNormalNot activated15≥ 37NoNoNoPhimosisPrepubescent at 5 yHomogenous but less reflectant since 11 yNot activated16≥ 37NoBilat (3 y)Bilateral orchidopexy 4y. Left relapse 5 yNoPrepubescent at 7 yNormalNot activated19≥ 37NoRightGonadoreline, effective. Right relapse right orchidopexy 13y + hernioplastic. No relapseInguinal herniaPubescent at 30 y G5NormalNot activated22≥ 37NoLeft (2 y)Spontaneously solved. No relapseInguinal herniaPubescent at 15 y G4NDNot activated24≥ 37NoBilat (5 y)Bilateral orchidopexy 5 y. No relapseNoPubescent---early onset **(**at 11 y G4)Hyperreflectant spots (seminiferous tubule fibrosis)Physiologic activation28UnkNoNoNAMicropenisCDGP; 15 y after testosterone: G2P3A1NormalND31\> 37BilatNoUnkMicropenisCDGP; at 17 y: G3P3A2NormalPhysiologic activation33UnkNoNoNAMicropenisUnkNDND36\> 37NoNoNANoCDGP; at 17 y after testosterone: G4P4A2NDND40\> 37NoNoNANoPrepubescent at 14 yNormalND43\> 37BilatNo2 y bilateral orchidopexyNoPubescent at 12 y (G4P3A2), early onsetNDND57\> 37BilatNoNot done yet---performing follow-upMicropenisNormal mini-pubertyPrepubescent at 9 yNDND59\>37RightNo11 y right orchidopexyPhimosisPrepubescent at 11 yNDND62UnkLeftNo18 months left orchidopexyNoPrepubescent at 7 yNormalND68\> 37NoRight4 y right orchidopexyNoPrepubescent 4 y and 7 monthsNormalNot activated82\> 37BilatNoNot done yet---performing follow-upMicropenisUndervirilized scrotumSuspect hypogonadism hypogonadotropic (no mini-puberty)Prepubescent 1 y and 7 monthsNDNDOnly patients with urogenital abnormalities or alteration in puberty or patients who performed hormonal test/US testis scan are included in the tablePubertal stage was evaluated with Tanner stage. Hypothalamus-pituitary-gonads axis evaluation: physiologic activation means we registered LH values \> 1 mUI/ml, FSH values \> 2 mUI/ml and \< 10 mUI/ml, testosterone or estradiol levels adequate for age; not activated means LH values \< 1 mUI/ml, FSH values \< 2 mUI/ml, testosterone not detectable; normal mini-puberty means LH and FSH values similar to puberty values*WG* week gestation, *UT* undescended testis, *NA* not applicable, *ND* not done, *UNK* unknown. Cryptorchidism: *CUT* congenital undescended testis, *AUT* acquired undescended testis, in brackets the age of diagnosis, *Bilat* bilateral, *CDGP* constitutional delay of growth and puberty

Abdominal US scans performed in 10/35 female patients were normal with no abnormalities documented in ovaries, uterus, or vagina (Table [3](#Tab3){ref-type="table"}).Table 3Female sample, urogenital abnormalities at pelvic US scan, pubertal development, and hormonal testsN°Pelvic us scanOther urogenital diseasePubertal stagePrecocious pubertyTreatment with GnRH agonistDelayed pubertyHypothalamus-pituitary-gonads axis3NormalNoPubescent 15 y TS V RMNoNoNoND4NormalNoPubescent 12 y TS V RMYes (8 y)Yes (8--11 y)NoND13NormalNoPubescent 10 y, B4 P2--3NoNoNoPhysiologic activation17NormalNoPrepubescent 3 yNoNoNoND20NormalNoPubescent RMNoNoNoPhysiologic activation21NormalNoPubescent IM\#Yes (8 y)NoNoPhysiologic activation42NormalNoPubescent 14 y, RMNoNoNoPhysiologic activation45NormalPolycystic kidney diseasePubescent at 15 y, RMNoNoNoND53NormalNoPubescent at 9 y, A1P2B3Yes (9 y)Yes (9 y--ongoing)NoNormal*ND* not done, *TS* Tanner stage, *RM* regular menses, *IM* irregular mensesOnly patients who performed US pelvic scan and/or hormonal tests were included in this table (for complete female sample see table in electronic supplemental material). In the column precocious puberty, the age of onset is reported in brackets\# patient n° 21 presented irregular menstrual cycles with prolonged periods of amenorrhea associated with hyperinsulinism, hirsutism, and hyperandrogenism. Polycystic ovary syndrome was suspected, and the patient was treated with cyproterone acetate and transdermal estradiol

In terms of pubertal development, data were available for 33 females and 48 males. In the overall population 28/81 had achieved puberty and 52/81 are still prepubescent (aged less than 14 years). Among female patients, 51.5% are still prepubescent (age ≤ 10 years) while 47.0% presented spontaneous pubertal progression (Table [3](#Tab3){ref-type="table"}). Among these, 3/16 presented early onset of puberty (at 8 years) and 2/3 were treated with gonadotropin-releasing hormone agonists. Among the male patients (Table [2](#Tab2){ref-type="table"}), 73% are still prepubescent (age \< 14 years). Nine patients presented spontaneous pubertal development of whom 2 showed early onset of puberty (at 9 years). Three patients presented delayed onset of puberty but appropriate progression (constitutional delay in growth and puberty) of whom 2 were treated with testosterone inducing the onset of puberty.

Hormonal data are available in 20 patients (Table [4](#Tab4){ref-type="table"}). In 9 pubescent patients (5 females, 4 males) hormonal tests showed physiologic activation of the hypothalamic-pituitary-gonadal axis. In 11 prepubescent patients (11 males), LH, FSH, and testosterone or estradiol resulted low. None of the patients had raised FSH values. No patient with delayed puberty presented hypogonadotropic hypogonadism (HH) although one patient with delayed puberty was not investigated (patient n° 40---age 14 years). Three patients with micropenis and bilateral cryptorchidism underwent blood tests within the first 6 months of life (during mini-puberty), and 2 presented physiologic activation of hypothalamic-pituitary-gonadal axis (Table [2](#Tab2){ref-type="table"}). In one patient, HH was suspected, and testosterone treatment was commenced (the patient is 1 year old).Table 4Puberty and hormonal tests in male and female patientsN°SexPubertal stageHypothalamus-pituitary-gonads axis2MPubescent at 15 y (G2P4)Physiologic activation5MPubescent at 15 y (G5)Physiologic activation6MPrepubescent at 10 yNot activated7MPrepubescent at 11 yNot activated9MPrepubescent at 9 yNot activated10MPrepubescent at 8 yNot activated11MPrepubescent at 9 yNormal mini-pubertyNot activated12MPrepubescent at 13 yNot activated13FPubescent 10 y, B4 P2--3Physiologic activation14MPrepubescent at 8 yNot activated15MPrepubescent at 5 yNot activated16MPrepubescent at 7 yNot activated19MPubescent at 30 y (G5)Physiologic activation20FPubescent, regular mensesPhysiologic activation21FPubescent, irregular menses (polycystic ovary syndrome)Physiologic activation24MPubescent at 10 y (G1--2)Physiologic activation42FPubescent 14 y, regular mensesPhysiologic activation53FPubescent at 9 y: A1P2B3Physiologic activation57MPrepubescent at 9 yNormal mini-pubertyNot activated82MPrepubescent 1 y and 7 monthsSuspected hypogonadotropic hypogonadism, no mini-puberty (testosterone treatment)Only patients who performed hormonal tests were included in this table. Pubertal stage evaluated with Tanner stage. Hypothalamus-pituitary-gonads axis evaluation: physiologic activation means we registered LH values \> 1 mUI/ml, FSH values \> 2 mUI/ml and \< 10 mUI/ml, testosterone or estradiol levels adequate for age; not activated means LH values \< 1 mUI/ml, FSH values \< 2mUI/ml, testosterone or estradiol not detectable; normal mini-puberty means LH and FSH values similar to puberty values

Discussion {#Sec4}
==========

Currently, there are no studies in the literature evaluating genital development or pubertal progression in ADA-SCID patients. No abnormalities of the gonads, uterus, and vagina were detected in the female subgroup, even if these data should be taken with caution since only a minor proportion of female subjects was studied. Therefore, we cannot exclude the association of urogenital abnormalities in female ADA-SCID. Conversely, we identified a high proportion of congenital and acquired undescended testes. In particular, the incidence of congenital undescended testes was higher in our cohort (22%) compared with healthy full-term neonates (0.5--4%, few authors report incidence up to 9%) \[[@CR6]--[@CR8]\]. Moreover, while in the general population 70--80% of undescended testes resolve spontaneously with only 23% requiring orchidopexy, the proportion of ADA-SCID patients eventually requiring orchidopexy was higher, with 64% of finally requiring surgery.

A higher incidence of congenital undescended testes is detected in premature neonates (up to 45%) \[[@CR6], [@CR7]\] but all patients with cryptorchidism in our sample were born at term (Table [2](#Tab2){ref-type="table"}). Congenital cryptorchidism is a manifestation of numerous clinical syndromes; the ratio of non-syndromic to syndromic cryptorchidism is described to be greater than 6:1 \[[@CR7]\]. In our sample there is high percentage of consanguinity (54% of patients with congenital undescended testes have consanguineous parents, Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Given the high rate of consanguinity in our cohort we cannot rule out the possibility of an additional inherited defect accounting for this increased incidence. However, even in patients without consanguineous parents, the incidence remains high compared with the general population (5/51, 10%).

Considering the pathogenesis, cryptorchidism is due to aberrant embryological development. The embryology of testicular descent is complex involving numerous anatomical structures and hormones \[6--7\]. Androgens are known to play a role in this as HH and panhypopituitarism are associated with bilateral cryptorchidism \[[@CR9]\]. Also, the possibility that environmental chemicals interfere with normal reproductive tract development has been raised \[[@CR7]\]. We feel we can exclude the hypothesis of HH here as we did not detect a delay in puberty usually associated with HH. Thirty-five percent of our patients entered spontaneous pubertal development and progression with adequate hormone levels; the remaining patients are aged 14 years or less. One can hypothesize that ADA may play a role in testicular embryological development/descent, and/or it is possible that toxic purine metabolites could interfere with this process.

In our population, we also identified a high incidence of acquired undescended testis (16%), with 87% of cases requiring orchidopexy. In a healthy population, acquired undescended testes are reported to occur in 1--3% of cases \[[@CR8]\]. Acquired undescended testes have a different pathogenesis compared with congenital undescended testes \[[@CR7]\], mainly related to adhesions or increased stiffness/shortness of anatomical barriers involved. It is possible that metabolic abnormalities related to ADA deficiency could alter the histologic structure of these tissues. The toxic effect of ADA metabolites has been reported on different tissues, and it is well described how purinergic signaling plays an important role in fibrosis damage of several organs (skin, heart, liver, and lung) during tissue repair. For example, the profibrotic role of ADA deficiency in the lung has been clearly shown in an animal model with adenosine deaminase-deficient mice developing adenosine-dependent pulmonary fibrosis due to accumulation of ADA metabolites \[[@CR10], [@CR11]\]. We can hypothesize that ADA deficiency could cause fibrosis in tissues that are crossed by testes, increasing the stiffness of the physiologic anatomical barriers.

In our patients receiving PEG-ADA ERT, BMT, or GT (with or without conditioning), FSH was not elevated. Thus, in our sample, neither ADA deficiency nor the treatments received negatively affected pubertal development or gonadic function. We did not perform specific tests to evaluate fertility in our cohort, mainly due to the young age of the patients. We can assume that our patients have functional endocrine regulation of puberty as they have normal pubertal development and normal testosterone or estradiol levels. The oldest patient is 30 years, but the mean age of the group is 19 years. However, we cannot know whether a dysfunction of endocrine gonadal component will have a later onset. No data are available in the literature regarding fertility in ADA-SCID. For patients undergoing BMT, there is a risk of infertility which of infertility is higher (\> 80%) in patients treated with conditioning regimens containing TBI, high-dose cyclophosphamide, melphalan, and busulfan. The use of a reduced-intensity conditioning regimen is expected to decrease HSCT-related side effects. Recently, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation has established recommendations for the diagnosis and pre-emptive procedures that should be offered to all children and adolescents in Europe who undergo life-saving allogeneic SCT \[[@CR12]\]. Emerging reports describe fertility and gonadal function in transplanted SCID \[[@CR13]--[@CR15]\], but actually, no specific studies on ADA-SCID have been performed. We recommend that these aspects deserve special attention considering the systemic manifestations of the condition (ADA-SCID) and the potential effects of its treatments on gonadal function.

In the literature, excess of adenosine in murine penile erectile tissues has been described associated with priapism \[[@CR16]\]: This study highlights how adenosine deaminase plays a biological role in different tissues and systems. Considering our sample's age, we did not analyze the erectile dysfunction.

The major limit of this report is the number of patients evaluated: We recognize that this study is based on limited sample size, but it is expected considering that ADA-SCID is an ultra-rare disease (from 1:200,000 to 1:1,000,000 births).

Conclusion {#Sec5}
==========

In summary, this report describes the high incidence of urogenital abnormalities in a cohort of male ADA-SCID patients, which likely represents systemic manifestations of ADA-SCID. We identified a high incidence of cryptorchidism in our male patients with no urogenital abnormalities noted in females. Spontaneous and age appropriate pubertal development occurred in most females and males with a few cases of precocious or delayed puberty noted. We recommend regularly evaluating pubertal state as part of the complete physical examination in ADA-SCID patients. If cryptorchidism is present, we suggest undertaking specialist urologic evaluation as soon as possible. Patients with cryptorchidism have an increased risk of progressive infertility, testicular malignancy, and torsion \[[@CR8]\]; successful relocation of the testes may reduce these potential long-term sequelae. Considering the impact urogenital and pubertal abnormalities can have on patients' quality of life, we feel it is essential to include relevant history taking, clinical examination, and endocrine investigations in ADA-SCID patients to detect any abnormalities, initiate early treatment, and prevent long term complications.
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ADA

:   Adenosine deaminase

ADA-SCID

:   Severe combined immunodeficiency due to adenosine deaminase deficiency

PEG-ADA

:   Polyethylene glycol-conjugated adenosine deaminase

GT

:   Gene therapy

BMT

:   Bone marrow transplantation

HH

:   Hypogonadotropic hypogonadism

LH

:   Luteinizing hormone

FSH

:   Follicle-stimulating hormone
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